Alimera Sciences's EBIT per Share for the
three
months ended in Dec. 2023 was $0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.45.
During the past 3 years, the average EBIT per Share Growth Rate was 8.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 35.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 43.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Alimera Sciences's EBIT per Share or its related term are showing as below:
ALIM'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -25.6 Med: 29.3 Max: 73.6
Current: 8.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Alimera Sciences was 73.60% per year. The lowest was -25.60% per year. And the median was 29.30% per year.
ALIM's 3-Year EBIT Growth Rate is ranked better than 50.12% of 852
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs ALIM: 8.10
Alimera Sciences's EBIT for the
three
months ended in Dec. 2023 was $0.98 Mil.
Alimera Sciences EBIT per Share Historical Data
The historical data trend for Alimera Sciences's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alimera Sciences (NAS:ALIM) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Alimera Sciences EBIT per Share Related Terms
Thank you for viewing the detailed overview of Alimera Sciences's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Alimera Sciences (Alimera Sciences) Business Description
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALIM has been successfully added to your 